EGFR and cancer: Co‐culture and conditioned medium experiments demonstrate that PCs reduce TKI effectiveness in EGFR‐mutated cancer cells, a reversible phenomenon through silencing IL32 expression in PCs or depleting the IL32 receptor β5‐integrin on cancer cells, thereby restoring cancer cell sensitivity.